Veranova Breaks Ground on $50M ADC Expansion at Devens Site

• Veranova has broken ground on a 9,000-square-foot expansion of its Devens, Massachusetts site to support ADC and bioconjugate development.

• The combined investment of over $50 million is expected to create up to 70 new jobs and enhance domestic manufacturing infrastructure.

Veranova has begun construction on a major expansion of its facility in Devens, Massachusetts, aimed at enhancing its capabilities in the development and production of complex therapies, including antibody-drug conjugates (ADCs).

The groundbreaking event, held on 18 June 2025, brought together government officials, life sciences leaders, and local representatives. The new 9,000-square-foot expansion will include a process development laboratory and two cGMP suites designed for highly potent compounds and advanced therapeutics.

This latest initiative follows Veranova’s earlier announcement of a complementary investment in bioconjugation capabilities at the same site. Together, these expansions represent more than $50 million in capital investment and are expected to create up to 70 jobs. The facility will strengthen domestic capacity for manufacturing advanced pharmaceutical ingredients.

Congresswoman Lori Trahan (MA-03), who attended the ceremony, remarked: “The fight to end cancer once and for all depends on trailblazers like Veranova, where innovative work in specialty medications is reshaping treatment options for cancer and rare diseases.”

Mike Riley, CEO of Veranova, added: “By enhancing our capabilities in Devens, we’re not only investing in innovation and growth, but also strengthening domestic infrastructure for the production of critical medicines like ADCs and other highly potent compounds.”

The Devens site currently offers cGMP laboratories, kilo labs for clinical and commercial scale, and multi-purpose production suites.